Reply to 'Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting'

被引：3
|
作者：
Ehdaie, Behfar [1 ]
Carlsson, Sigrid [1 ,2 ,3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
[3] Univ Gothenburg, Inst Clin Sci, Dept Urol, Sahlgrenska Acad, Gothenburg, Sweden
来源：
PROSTATE CANCER AND PROSTATIC DISEASES | 2018年 / 21卷 / 03期
基金：
美国国家卫生研究院;
关键词：
D O I：
10.1038/s41391-018-0052-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：446 / 447
页数：2
相关论文
共 13 条
  • [11] PERFORMANCE OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) RISK CALCULATOR FOR HIGH GRADE PC IN A CLINICAL SETTING AND THE ADDITIONAL VALUE OF THE PROSTATE HEALTH INDEX (PHI)
    Roobol, Monique J.
    Semjonow, Axel
    Bangma, Chris H.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S268 - S268
  • [12] Clinical cut-offs of isoform [-2]proPSA (p2PSA) derivatives, namely %p2PSA and PHI (Prostate Health Index) for guiding biopsy decision in Caucasian population
    Lughezzani, G.
    Lazzeri, M.
    Scattoni, V
    Larcher, A.
    Gadda, G.
    Nava, L.
    Lista, G.
    Bini, V
    Freschi, M.
    Rigatti, L.
    Rigatti, P.
    Guazzoni, G.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E909 - U911
  • [13] [-2]PROPSA (P2PSA) AND ITS DERIVATIVES %P2PSA AND PHI (PROSTATE HEALTH INDEX) IN A REAL CLINICAL SETTING OF CONTEMPORARY MEN UNDERGOING PROSTATE BIOPSY FOR SUSPECTED PROSTATE CANCER. A SINGLE HIGH-VOLUME CENTER EXPERIENCE
    Nava, Luciano
    Lazzeri, Massimo
    Scattoni, Vincenzo
    Maccagnano, Carmen
    Lughezzani, Giovanni
    Buffi, Nicolo
    Fabbri, Fabio
    Larcher, Aiessandro
    Bini, Vittorio
    Cestari, Andrea
    Montorsi, Francesco
    Rigatti, Patrizio
    Guazzoni, Giorgio
    JOURNAL OF UROLOGY, 2011, 185 (04): : E919 - E920
12